Clearmind Advances Alcohol Use Disorder Trial with Phase IIa Initiation — Clearmind Medicine Inc.

Event summary

Clearmind has initiated Phase IIa of its CMND-100 trial for Alcohol Use Disorder (AUD), enrolling six patients across two medical centers.
One-third of Part C (Phase IIa) is already enrolled, following successful completion of the safety phase in healthy volunteers.
CMND-100 is a non-hallucinogenic psychedelic-derived neuroplastogen designed for scalable treatment of AUD.
The trial is structured as a four-part Phase I/IIa study, evaluating safety, tolerability, and preliminary efficacy.

The big picture

Clearmind’s progress in the CMND-100 trial reflects the broader push for scalable, non-hallucinogenic treatments in addiction medicine. The company’s focus on AUD, a condition with limited effective therapies, aligns with increasing investment in psychedelic-derived compounds for neuropsychiatric disorders. Success in this trial could validate Clearmind’s approach and attract further capital in a competitive sector.

What we're watching

Trial Momentum: The pace at which Clearmind completes Phase IIa enrollment will determine the timeline for efficacy data.
Regulatory Pathway: Whether CMND-100’s non-hallucinogenic profile accelerates approval compared to traditional psychedelics.
Market Differentiation: How Clearmind positions CMND-100 against competitors in the growing psychedelic therapeutics space.